Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helene Karcher

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Alzheimer'S Disease : JAD|June 30, 2020
Ethical and Social Implications of Using Predictive Modeling for Alzheimer's Disease Prevention: A Systematic Literature ReviewZuzanna Angehrn, Jelena Sostar, Clementine Nordon, et al.
Acta Ophthalmologica|September 19, 2022
Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studiesCaroline R Baumal, Torben Lykke Sørensen, Helene Karcher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
The "Efficacy-Effectiveness Gap": Historical Background and Current ConceptualizationClementine Nordon, Helene Karcher, Rolf H H Groenwold, et al.
Pharmaceutics|January 25, 2025
Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF TreatmentQing Wen, Helene Karcher, David M Wright, et al.
Schizophrenia Research|July 18, 2017
Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: A case study using the SOHO databaseClementine Nordon, Thomas Bovagnet, Mark Belger, et al.
JAMA Network Open|September 13, 2021
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysisJulie Martinkova, Frances-Catherine Quevenco, Helene Karcher, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|March 4, 2025
Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence StudyJamuna K Krishnan, Gerard J Criner, Bilal H Lashari, et al.
Ophthalmology and Therapy|May 28, 2025
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter StudyMasayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, et al.
Ophthalmology and Therapy|March 23, 2024
Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® RegistryMarco A Zarbin, Mathew W MacCumber, Helene Karcher, et al.
Ophthalmology|April 22, 2023
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® RegistryMathew W MacCumber, Charles C Wykoff, Helene Karcher, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Alzheimer'S Disease : JAD|June 30, 2020
Ethical and Social Implications of Using Predictive Modeling for Alzheimer's Disease Prevention: A Systematic Literature ReviewZuzanna Angehrn, Jelena Sostar, Clementine Nordon, et al.
Acta Ophthalmologica|September 19, 2022
Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studiesCaroline R Baumal, Torben Lykke Sørensen, Helene Karcher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
The "Efficacy-Effectiveness Gap": Historical Background and Current ConceptualizationClementine Nordon, Helene Karcher, Rolf H H Groenwold, et al.
Pharmaceutics|January 25, 2025
Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF TreatmentQing Wen, Helene Karcher, David M Wright, et al.
Schizophrenia Research|July 18, 2017
Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: A case study using the SOHO databaseClementine Nordon, Thomas Bovagnet, Mark Belger, et al.
JAMA Network Open|September 13, 2021
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysisJulie Martinkova, Frances-Catherine Quevenco, Helene Karcher, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|March 4, 2025
Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence StudyJamuna K Krishnan, Gerard J Criner, Bilal H Lashari, et al.
Ophthalmology and Therapy|May 28, 2025
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter StudyMasayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, et al.
Ophthalmology and Therapy|March 23, 2024
Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® RegistryMarco A Zarbin, Mathew W MacCumber, Helene Karcher, et al.
Ophthalmology|April 22, 2023
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® RegistryMathew W MacCumber, Charles C Wykoff, Helene Karcher, et al.
Pageof 4